Sweden's Redsense Q4 net sales drop 52% on currency headwinds

Redsense Medical AB (publ)

19/02/2026 07:39

Overview

Sweden-based medical device maker's Q4 net sales fell significantly yr/yr

Company reported Q4 operating loss amid restructuring and external challenges

Company granted regulatory approval for Clamp System in Australia

Outlook

Redsense aims to increase end-customer usage in the U.S. in 2026

Company plans to launch Redsense Clamp in new markets outside the U.S.

Redsense to implement revised pricing structure from February 2026

Result Drivers

RESTRUCTURING IMPACT - Redsense's restructuring efforts aimed at operational alignment affected Q4 results, with a focus on long-term execution

CURRENCY FLUCTUATIONS - Currency effects impacted Redsense's financial results, with USD/SEK fluctuations affecting reported figures

LOGISTICS CHALLENGES - Elevated logistics and customs costs affected gross margins, prompting a revised pricing structure

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
SEK 6.04 mln
Q4 EPS
-SEK 0.11
Q4 Net Income
-SEK 1.84 mln
Q4 EBIT
-SEK 1.95 mln


Press Release: ID:nWkrbFF98x

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)